Pharmaceuticals
Sintilimab in Combination with Chemotherapy Meets Overall Survival Primary Endpoint in the Global Phase 3 ORIENT-15 Study for the First-Line Treatment of Esophageal Squamous Cell Carcinoma
SAN FRANCISCO and SUZHOU, China, June 23, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2021-06-23 09:16
21009
Global Water Scarcity and Hospitalization Rates Stimulate the Polymeric Membranes Market
The demand for water treatment membranes and medical membranes will drive the global market, says Frost & Sullivan SANTA CLARA, Calif., June 23, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis of the global polymeric membranes market finds that the drive to achieve a circular economy and...
2021-06-23 00:14
2316
Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform
ST. CHARLES, Mo., June 22, 2021 /PRNewswire/ -- Eurofins Discovery, the leading provider of products and services to the drug discovery industry and a Eurofins Scientific (EUFI.PA) company, and ImmunoPrecise Antibodies (Nasdaq:IPA), the market leader in full-service therapeutic discovery and deve...
2021-06-22 20:28
5587
Alfasigma acquires the European license for bentracimab from PhaseBio
BOLOGNA, Italy, 22 giugno 2021 /PRNewswire/ -- Alfasigma has entered into an exclusive licensing agreement with PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), for the commercialization of bentracimab in 49 countries acrossEurope and other key markets. PhaseBio is a biopharmaceutical company focu...
2021-06-22 14:45
2963
Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira®
SHANGHAI, June 22, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced dosing of the first patient inEurope in its multinational, multicenter, Phase III clinical trial (APRICITY) of its photodynamic drug-device combination product APL-1702, Cevira® which is being developed for ...
2021-06-22 13:15
1584
2021 ASCO - AnchorDx Unveils Robust Validation Result of Multi-cancer Screening Technology AURORA
GUANGZHOU, China, June 21, 2021 /PRNewswire/ -- At this year's American Society of Clinical Oncology (ASCO) Annual Meeting 2021 (June 4-8), AnchorDx, a world-leading developer of cancer screening and early detection solutions, unveiled further validation results on the generalization performance ...
2021-06-21 23:19
621
I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board
SHANGHAI and GAITHERSBURG, Md., June 21, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the appointment ofAndrew Zhu, MD, PhD, to the Company's ...
2021-06-21 20:00
7841
RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19
TEL AVIV, Israel and RALEIGH, NC, June 21, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
2021-06-21 19:00
7970
HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda(R) in China) for Advanced Pancreatic Neuroendocrine Tumors
HONG KONG, June 21, 2021 /PRNewswire/ -- HUTCHMED (China) Limited ("HUTCHMED
2021-06-21 15:15
5624
CStone announces first prescriptions of precision therapy GAVRETO® (pralsetinib) issued across China for the treatment of adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer after platinum-based chemotherapy
SUZHOU, China, June 21, 2021 /PRNewswire/ -- GAVRETO® (pralsetinib), a precision therapy discovered by CStone Pharmaceuticals' partner Blueprint Medicines, had the first batch of prescriptions issued at Guangdong Province People's Hospital and around 100 other hospitals acrossChina. GAVRETO is al...
2021-06-21 13:06
3642
Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology
SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2021-06-21 08:00
8141
CARsgen Therapeutics officially listing on HKEX
HONG KONG, June 19, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited
(the "Company", stock code: 2171.HK) today announced that the Company's Shares
have been traded on the Main Board of The Stock Exchange of Hong Kong Limited
under the stock code "2171.HK".
2021-06-19 02:57
10332
Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants
MELBOURNE, Australia, June 18, 2021 /PRNewswire/ -- New data released today
shows thatAustralia's Viraleze™ anti-COVID nasal spray is more than 99.9%
effective against three of the four deadliest variants of the SARS-CoV-2 virus.
2021-06-18 14:16
15038
Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants
MELBOURNE, Australia, June 18, 2021 /PRNewswire/ -- New data released today
shows thatAustralia's Viraleze™ anti-COVID nasal spray is more than 99.9%
effective against three of the four deadliest variants of the SARS-CoV-2 virus.
2021-06-18 14:04
14704
Gilead Sciences Announces Subanalyses of Safety and Efficacy Data from a Phase 2 Study of Chronic Hepatitis B Patients with Renal or Hepatic Impairment Switching to Vemlidy(r)
HONG KONG, June 18, 2021 /PRNewswire/ -- Gilead Sciences, Inc. today announced new sub-analysis data from a Phase 2 open-label study (GS-US-320-4035; NCT03180619), evaluating the safety and efficacy of switching to Vemlidy®# (tenofovir alafenamide 25 mg, TAF) from tenofovir disoproxil fumarate (T...
2021-06-18 10:00
2457
Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment
BEIJING and SHANGHAI and BOSTON, June 18, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) has announced that the first two patients have been dosed in the Phase 1/2a clinical trial ofSHP2 inhibitor JAB-3312 in combination with PD-1 antibody Pembrolizumab and MEK inhibitor Binimetinib respe...
2021-06-18 08:31
5018
Innovent Announces First Patient Dosed in the Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion
SAN FRANCISCO and SUZHOU, China, June 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2021-06-18 08:00
3905
Envirotainer Announces Cathay Pacific as First Asian carrier for the recently released Releye® RLP container
STOCKHOLM, June 17, 2021 /PRNewswire/ -- Envirotainer, the global market leader in secure cold chain solutions for air transportation of pharmaceuticals, today announced that Cathay Pacific has approved the Envirotainer Releye® RLP for carriage on its fleet of aircraft. Cathay Pacific can now off...
2021-06-17 19:49
1851
Elekta radiotherapy system designed for changing cancer landscape now available for U.S. patients
ATLANTA, June 17, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that its Elekta Harmony* radiation therapy system recently received U.S. FDA 510(k) clearance, paving the way for U.S. clinics to harness the system to treat a comprehensive range of indications using the latest radiotherap...
2021-06-17 14:38
15784
Gannex Announces Positive Topline Results of the U.S. Phase I Trial of NASH Drug ASC42, an FXR Agonist
SHANGHAI, June 16, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D and commercialization of new drugs in the field of non-alcoholic steatohepatitis (NASH), today announces positive topline results of safety and pharmacodynamic ...
2021-06-16 21:00
3714
Week's Top Stories
Most Reposted
AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 301 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 296 media titles]
2026-01-22 15:16
Infobip strengthens leadership to drive growth and innovation
[Picked up by 281 media titles]
2026-01-16 11:00
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 279 media titles]
2026-01-20 15:40
Novo Holdings Invests in Surya Hospitals to Strengthen Access to High-Quality Women's and Children's Healthcare in India
[Picked up by 276 media titles]
2026-01-20 09:00
